Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus plantarum UALp-05M

What does the research say about Lactobacillus plantarum UALp-05M?

2 health outcomes synthesised

Research on Lactobacillus plantarum UALp-05M covers 2 health outcomes, with the strongest evidence supporting its potential for improving growth performance. Across 4 studies—all in animal models including broiler chickens and piglets—consistent beneficial effects were observed, though no effective dose range has been established. Evidence for reduced inflammation levels is based on 3 preclinical studies, all showing beneficial effects but limited to in vitro or animal models.

Strongest evidence

The evidence for Lactobacillus plantarum regarding Improved Growth Performance is classified as low strength but is the most robust among the outcomes, supported by 4 studies. All 4 studies reported beneficial effects, with 3 of the 4 showing statistically significant improvements. Effect sizes ranged from moderate to large. However, all studies were conducted in animal models (broiler chickens, weaning pigs, and Labeo rohita juveniles), and no human trials are available. Doses and study durations were inconsistently reported.

Mixed or weaker evidence

Reduced Inflammation Levels has low evidence strength based on 3 preclinical studies (2 in vitro, 1 in vivo). All 3 studies reported beneficial effects on reducing inflammatory markers, with effect sizes ranging from moderate to large. The single statistically significant study (in Caco-2 cells) showed large inhibition of pro-inflammatory cytokines. No human trials were identified.

Effective dose patterns

A consistent effective dose could not be determined for any outcome, as dosing was not reliably reported across studies. No cross-cutting dose insights emerged.

Population insights

All evidence for growth performance comes from agricultural animal populations (poultry, swine, fish). The relevance of these findings to human growth or health is unknown. No specific human populations were studied for either outcome.

Notable caveats

  • Publication bias is a concern for both outcomes, as null-result studies tend to be unpublished.
  • Evidence bases are small (3-4 studies), so conclusions are preliminary.
  • No human studies are available for either outcome—applicability to humans is uncertain.

Frequently asked

  • What is Lactobacillus plantarum UALp-05M good for according to research?
    Research has examined two potential benefits: improved growth performance (based on 4 animal studies) and reduced inflammation levels (based on 3 preclinical studies). All studies reported beneficial effects, but all evidence is from animal or laboratory models, not human trials.
  • What dose of Lactobacillus plantarum UALp-05M is typically used in studies?
    No consistent effective dose has been reported in the available studies. Dosing information was often not provided or was inconsistent across the 7 total studies. Therefore, no dose recommendations can be derived from this evidence.
  • Who benefits most from Lactobacillus plantarum UALp-05M?
    Based on current research, benefits for growth performance were observed in broiler chickens, weaning pigs, and Labeo rohita juveniles. For inflammation reduction, studies used Caco-2 cells and animal models. No human populations have been studied, so it is unknown whether these benefits translate to humans.
  • Are there caveats or limitations in the research on Lactobacillus plantarum UALp-05M?
    Yes. The evidence base is very small (3-4 studies per outcome), all studies are preclinical or animal models with unknown human relevance, and publication bias is likely since null results are often not published. Conclusions should be considered preliminary.
  • Does Lactobacillus plantarum UALp-05M help with improved growth performance?
    In animal studies, all 4 studies reported beneficial effects on growth performance, with 3 showing statistically significant improvements. Effect sizes were moderate to large. However, no human studies exist, so the evidence does not support use for human growth outcomes.
  • Does Lactobacillus plantarum UALp-05M help with reduced inflammation?
    Three preclinical studies (2 in vitro, 1 in vivo) all reported reductions in inflammatory markers, with effect sizes ranging from moderate to large. The only statistically significant finding was from a cell culture study showing large inhibition of pro-inflammatory cytokines. Human trials are lacking.

Most-studied combinations with Lactobacillus plantarum UALp-05M

most supplement research is combination research
Also studied with:Lactobacillus plantarum KABP-061 (9), Lactobacillus plantarum DR7 (8)
Back to top